Lucid Diagnostics, Inc. (LUCD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.94-1.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · LUCD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 324.5% |
| Our one-year growth estimate | diamond | 88.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 235.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is on a run of consecutive earnings misses and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
LUCD — earnings miss
Dated 2026-08-13
is incorporated herein by reference. The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Why it matters: How the company uses this money shows how well it manages finances and supports growth.
Watch forManagement says they use the money well. It helps with working capital and operations.
Also watch forManagement gives no updates or shows that funds are not used well.
Why it matters: If sector revenue growth picks up, it could benefit Lucid's market position.
Supportive ifSector revenue growth speeds up to 10% or more.
Worry ifSector revenue growth keeps slowing down below 5%.
Why it matters: More coverage policies would help sales and market access.
Supportive ifMore health plans have announced new commercial coverage for EsoGuard.
Worry ifNo new coverage policies for EsoGuard are secured. This limits market access.
Why it matters: Improved revenue growth would show progress in converting demand into revenue. This is key for the company's future.
Supportive ifQ2 revenue growth exceeds $1,256,000, showing improvement from Q1.
Worry ifQ2 revenue growth is below $1,256,000. This shows ongoing struggles.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$192 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $518 loss on $10,000 · 5.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,071 loss on $10,000 · 40.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A high cash burn rate may show financial problems and affect future plans.
Worry ifCash and cash equivalents remain above $30 million by the end of Q3 2026.
Less concerning ifCash and cash equivalents fall below $30 million by the end of Q3 2026.
Why it matters: A drop in cash reserves could indicate financial strain. This affects Lucid's ability to fund operations and growth.
Worry ifCash reserves reported below $30 million in Q3 2026.
Less concerning ifCash reserves reported above $30 million in Q3 2026.
Why it matters: Using the $18 million raised well can improve the company's finances.
Watch forManagement provides a clear plan on how the offering proceeds will be deployed.
Also watch forNo updates on how the money is used raise concerns about cash flow.
Why it matters: How Lucid uses the $18 million from the stock sale affects its growth and operations.
Watch forLucid gives a clear update on how it is using the money from the stock sale.
Also watch forLucid does not give updates or shows poor use of the stock sale money.
Why it matters: A continued drop in revenue shows the company struggles to convert demand into sales. This is key for growth.
Worry ifQ2 revenue decreases year over year worse than the previous decline of 16.4%.
Less concerning ifQ2 revenue stabilizes or grows year over year.
Why it matters: Continued revenue growth is key to converting demand into actual sales. It shows commercial success.
Supportive ifEsoGuard revenue for Q3 2026 exceeds $1.5 million.
Worry ifEsoGuard revenue for Q3 2026 is less than $1.5 million.
Why it matters: Watching operating costs helps us understand financial health. It shows how well costs are managed.
Worry ifOperating expenses for Q3 2026 are less than $14.3 million.
Less concerning ifQ3 2026 operating costs go over $14.3 million.
Why it matters: Test volume shows demand for EsoGuard testing. It also shows how well it operates.
Watch forEsoGuard test volume in Q3 2026 exceeds 2,770 tests.
Also watch forEsoGuard test volume in Q3 2026 falls below 2,770 tests.